FDA Approves AbbVie's Juvmo, First New Oral Parkinson's Drug Class in Decades

Parkinson's disease is a long-term brain condition that gradually damages movement control, often causing tremors, stiffness and balance issues. More than 11 million people live with the disease worldwide, according to AbbVie, including roughly 1 million in the United States. That US figure is projected to exceed 1.6 million by 2037. The condition is driven in part by the loss of dopamine, a vital brain chemical that naturally decreases in people with Parkinson's. For decades, clinicians have relied on levodopa and on dopamine agonists that arrived in the 1990s, including pramipexole, ropinirole and rotigotine. Those older drugs target D2 and D3 receptors, and their use has been linked to impulse-control disorders, somnolence, hallucinations and hypotension.

On 25 September 2026 the US Food and Drug Administration approved AbbVie's Juvmo, also known as tavapadon, a once-a-day pill for adults with Parkinson's disease. The approval makes Juvmo the first US-approved selective D1/D5 dopamine receptor partial agonist, and it gives the Parkinson's market its first new oral drug class in roughly three decades. The label covers monotherapy in early Parkinson's disease and adjunctive use with levodopa for adults with motor fluctuations. AbbVie gained access to tavapadon through its roughly $8.7 billion acquisition of Cerevel Therapeutics, a deal completed on 1 August 2024 at $45 per share. AbbVie submitted the new drug application for tavapadon on 26 September 2025, roughly one year before the approval.

Tavapadon works by mimicking dopamine, but it does so selectively. It binds D1/D5 receptors along the nigrostriatal pathway while avoiding D2/D3 overstimulation, which is linked to the troublesome side effects that have long complicated older dopamine agonists. The FDA's decision rested on data from AbbVie's late-stage TEMPO program, which evaluated the drug in both early and advanced Parkinson's disease. Common side effects reported in the trials included nausea, dizziness and headache.

Key Facts

Medscape reported on 1 April 2026 that results from two Phase 3 trials showed the selective dopamine D1/D5 partial agonist tavapadon improved motor symptoms in both early and advanced Parkinson's disease with a distinct safety profile. The findings of TEMPO-1 and TEMPO-3 were published online on 20 March 2026 in JAMA Neurology. TEMPO-1 tested tavapadon as monotherapy in 529 adults with early Parkinson's, with a mean age of 63.7 years and 35.3% women. At week 26, least-squares mean reductions in combined MDS-UPDRS Parts II and III scores were 9.7 points with 5 mg and 10.2 points with 15 mg, compared with a 1.8-point worsening with placebo. The treatment differences were 11.5 and 12.1 points, with p<0.001 for both. TEMPO-3 evaluated tavapadon as adjunctive therapy in 507 adults with a mean age of 64.9 years and 63% men. Participants had a mean disease duration of 6.7 years and were experiencing motor fluctuations on stable oral levodopa of 400 mg or more daily. Tavapadon increased daily good-on-time by 1.70 hours versus 0.60 hours for placebo, a difference of 1.10 hours with p<0.001, and reduced off-time by 1.88 hours versus 0.93 hours, a difference of 0.94 hours with p<0.001. Lead TEMPO-3 investigator Hubert H. Fernandez of Cleveland Clinic said tavapadon "has the potential to provide the efficacy that clinicians and patients enjoyed with its older predecessors, but with much less likelihood of developing idiosyncratic side effects."

Medscape reported on 17 July 2026 on the full Phase 3 TEMPO-2 results, which were published online on 15 July 2026 in Lancet Neurology. TEMPO-2 enrolled 304 adults aged 40 to 80 with early Parkinson's disease, defined as less than 3 years of disease duration, who were treatment-naive or had received less than 3 months of dopaminergic therapy. The primary endpoint, change from baseline to week 26 in the combined MDS-UPDRS Parts II and III score, improved significantly with tavapadon: a least-squares mean reduction of 10.3 points versus 1.2 points for placebo, a 9.1-point difference with p<0.0001. That difference exceeded the roughly 4.9-point threshold considered the minimum clinically important difference. Nearly half of tavapadon patients, 46%, rated themselves "much improved" or "very much improved" on the Patient Global Impression of Change, versus 19% on placebo.

Safety data from TEMPO-2 showed overall adverse events were more common with tavapadon, at 76% versus 55%, though most were mild or moderate. The most common events were nausea at 30%, headache at 17% and dizziness at 16%. Hallucinations occurred in 4% of tavapadon patients versus none on placebo, while rates of somnolence (3% versus 4%) and impulse control disorders (1% versus 0%) were low, consistent with the selective D1/D5 mechanism. No dyskinesia cases were observed. Discontinuation due to adverse events was 24% with tavapadon versus 4% with placebo, mostly during dose titration. An open-label extension, TEMPO-4, is evaluating long-term safety and efficacy.

Reuters reported on 25 September 2026 that the US Food and Drug Administration approved AbbVie's treatment for Parkinson's disease in adults, according to the regulator's website. The drug, tavapadon, will be sold under the brand name Juvmo and comes as a once-a-day pill. AbbVie did not respond to a Reuters request for comment on the drug's launch and pricing. Citi analysts had previously said the launch was expected in the third quarter of 2026, but that uptake was likely to be gradual as negotiations progressed on the drug's Medicare coverage. AbbVie continued to target more than $5 billion in combined Parkinson's disease sales, Citi added.

AlphaPilot reported on 25 September 2026 that the approval cleared a once-daily oral treatment roughly one year after AbbVie submitted the new drug application on 26 September 2025. ICER's California Technology Assessment Forum convenes on 1 October 2026 to vote on tavapadon's value and pricing, following a 16 September 2026 ICER report that judged the drug comparable to, but not cost-effective against, alternatives. That report derived a health-benefit price benchmark of $4,764 to $6,861 per year in the adjunctive setting.

Analysis

The approval of Juvmo is a genuine scientific milestone, but it is not a cure, and it does not render existing therapies obsolete. Tavapadon's selective D1/D5 mechanism is designed to sidestep the D2/D3 overstimulation that has been linked to impulse-control disorders, somnolence, hallucinations and hypotension. The TEMPO-2 data support that promise, with low rates of somnolence and impulse control disorders and no dyskinesia cases. Yet the same trial showed a 24% discontinuation rate due to adverse events, mostly during dose titration. That number is not trivial, and it suggests the drug still demands careful tolerability management in real-world practice.

What this really means is that the approval opens a new chapter in Parkinson's treatment, but its clinical and commercial success will hinge on execution, not just on novelty. The efficacy numbers are solid: a 9.1-point placebo-adjusted improvement in TEMPO-2, a 1.10-hour increase in good-on-time in TEMPO-3, and consistent signals across three Phase 3 trials. Still, the drug is not clearly more effective than older options on every measure, and its main selling point is a safety profile that may be easier to manage. Neurologists will need to weigh that profile against the familiar effects of levodopa and existing agonists, and against cost and coverage.

The pricing and access picture is equally important. ICER's 16 September 2026 report judged tavapadon comparable to, but not cost-effective against, alternatives, and set a health-benefit price benchmark of $4,764 to $6,861 per year in the adjunctive setting. That range will inform payer negotiations. Citi analysts expect gradual uptake as Medicare coverage negotiations proceed. AbbVie's $8.7 billion acquisition of Cerevel Therapeutics puts pressure on the company to deliver meaningful revenue, and AbbVie continues to target more than $5 billion in combined Parkinson's disease sales. Those targets depend on whether payers accept the drug's value story.

Why It Matters

For patients, the approval means a new oral option that works differently from the dopamine agonists that have dominated treatment since the 1990s. More than 11 million people live with Parkinson's disease worldwide, according to AbbVie, and roughly 1 million in the United States, a figure projected to exceed 1.6 million by 2037. A once-daily pill that selectively targets D1/D5 receptors could offer a better tolerated alternative for some patients, particularly those who cannot tolerate the impulse-control, sleepiness or hallucination risks associated with older agonists. The availability of a new drug class also gives clinicians another tool when tailoring therapy.

The approval also matters for AbbVie, which gained tavapadon through its roughly $8.7 billion acquisition of Cerevel Therapeutics. The company has said it targets more than $5 billion in combined Parkinson's disease sales, and Juvmo is the centrepiece of that ambition. A successful launch would validate AbbVie's bet on Cerevel's pipeline. A slow or disappointing rollout, by contrast, would raise questions about the acquisition price and about the commercial viability of a drug that enters a market with entrenched generic competition.

At a system level, the ICER review and the looming CTAF vote highlight the growing role of value assessment in US drug pricing. ICER's health-benefit price benchmark of $4,764 to $6,861 per year in the adjunctive setting will be cited by payers and possibly by policymakers. If AbbVie prices Juvmo above that range, it could face coverage restrictions that limit patient access. If it prices within the range, it may satisfy payers but leave revenue below the company's targets.

Next Up

ICER's California Technology Assessment Forum convenes on 1 October 2026 to vote on tavapadon's value and pricing, a decision that will shape early payer attitudes. In parallel, the open-label extension trial TEMPO-4 is evaluating long-term safety and efficacy, and its results will help determine whether the drug's tolerability profile holds up over time. AbbVie has not yet disclosed launch pricing or Medicare coverage strategy, and Citi analysts expect gradual uptake as negotiations proceed. Further out, the Parkinson's field will watch whether tavapadon's selective D1/D5 approach inspires additional investment in new mechanisms, but the real test will come in the clinic and in coverage decisions.